August 2011 -- Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD.
But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to understanding the causes of AD on molecular level. Taking into account AD complexity, it becomes clear that polypharmacology with drugs targeting different molecules could be the future treatment approach.
Otava offers 29 Alzheimer’s disease Targeted Libraries designed with Ligand-based and Receptor-based approach. These libraries contain only drug-like compounds. All molecules have enhanced potential for CNS bioavailability. Filtering by polar surface area parameter (PSA) which discriminates CNS penetrating compounds, we selected only those compounds having increased blood-brain barrier (BBB) permeability.
In this collection of targeted libraries we included those activities which can be divided into two Alzheimer’s treatment categories: (i) disease-modifying treatments that target and reduce the secondary pathologies of the disease, leading to the cessation or the reversal of disease progression; and (ii) symptomatic treatments that treat cognitive symptoms of the disease and protect from further cognitive decline.
We hope that Otava Targeted Libraries can help scientists and pharmaceutical companies racing to develop treatments that address the underlying Alzheimer’s disease processes.
Otava Ltd.
P.O. Box 88
Kyiv 187, 03187
Ukraine
OTAVA Ltd. is an international science-based chemical company founded in 1997. It has production laboratories and offices in Europe (Kiev, Ukraine) and North America (Toronto, Canada).
